147 related articles for article (PubMed ID: 12456956)
21. [Erythropoietin and radiotherapy].
Le Fur E; Albarghach MN; Pradier O
Cancer Radiother; 2010 Jan; 14(1):81-6. PubMed ID: 20018547
[TBL] [Abstract][Full Text] [Related]
22. The role of recombinant erythropoietin in childhood cancer.
Shankar AG
Oncologist; 2008 Feb; 13(2):157-66. PubMed ID: 18305061
[TBL] [Abstract][Full Text] [Related]
23. [Use of human recombinant erythropoietin in children with cancer].
Guyot D; Margueritte G
Arch Pediatr; 2005 Sep; 12(9):1376-82. PubMed ID: 16084072
[TBL] [Abstract][Full Text] [Related]
24. Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned?
Osterborg A
Med Oncol; 1998 Aug; 15 Suppl 1():S47-9. PubMed ID: 9785337
[No Abstract] [Full Text] [Related]
25. Perturbation of autocrine/paracrine loops of burst-forming units of erythroid-derived cells in rHuEPO-hyporesponsive hemodialysis patients.
Nakao K; Wada J; Ota K; Ichikawa H; Akagi S; Okamoto A; Hida K; Nagake Y; Makino H
Am J Kidney Dis; 2003 Mar; 41(3):624-36. PubMed ID: 12612986
[TBL] [Abstract][Full Text] [Related]
26. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review.
Bohlius JF; Langensiepen S; Engert A; Schwarzer G; Bennett CL
Best Pract Res Clin Haematol; 2005; 18(3):449-54. PubMed ID: 15792919
[TBL] [Abstract][Full Text] [Related]
28. Erythropoietin in clinical practice: current use, effect on survival, and future directions.
Oster HS; Hoffman M; Prutchi-Sagiv S; Katz O; Neumann D; Mittelman M
Isr Med Assoc J; 2006 Oct; 8(10):703-6. PubMed ID: 17125118
[TBL] [Abstract][Full Text] [Related]
29. Anemia in renal insufficiency.
Santoro A
Rev Clin Exp Hematol; 2002; Suppl 1():12-20. PubMed ID: 12735211
[TBL] [Abstract][Full Text] [Related]
30. Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response.
Vanstraelen G; Baron F; Willems E; Bonnet C; Hafraoui K; Frère P; Fillet G; Beguin Y
Exp Hematol; 2006 Jul; 34(7):841-50. PubMed ID: 16797411
[TBL] [Abstract][Full Text] [Related]
31. [Summary version of the Standards, Options and Recommendations for the use of recombinant erythropoietin (epoietin-alpha and beta, darbepoietin-alpha, EPO) in the management of anaemia in oncology - Update 2003].
Spaeth D; Casadevall N; Daouphars M; Marchal C; Marec-Berard P; Fabre N; Haugh M;
Bull Cancer; 2004 Feb; 91(2):179-88. PubMed ID: 15047458
[TBL] [Abstract][Full Text] [Related]
32. Erythropoietin and treatment of non-anemic conditions--cardiovascular protection.
Fliser D; Haller H
Semin Hematol; 2007 Jul; 44(3):212-7. PubMed ID: 17631185
[TBL] [Abstract][Full Text] [Related]
33. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response.
Brines M; Cerami A
J Intern Med; 2008 Nov; 264(5):405-32. PubMed ID: 19017170
[TBL] [Abstract][Full Text] [Related]
34. The erythropoietin receptor and its expression in tumor cells and other tissues.
Farrell F; Lee A
Oncologist; 2004; 9 Suppl 5():18-30. PubMed ID: 15591419
[TBL] [Abstract][Full Text] [Related]
35. Beneficial and ominous aspects of the pleiotropic action of erythropoietin.
Jelkmann W; Wagner K
Ann Hematol; 2004 Nov; 83(11):673-86. PubMed ID: 15322761
[TBL] [Abstract][Full Text] [Related]
36. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment.
Baron F; Frère P; Fillet G; Beguin Y
Clin Cancer Res; 2003 Nov; 9(15):5566-72. PubMed ID: 14654537
[TBL] [Abstract][Full Text] [Related]
37. Alternatives to blood product transfusion in the critically ill: erythropoietin.
Stubbs JR
Crit Care Med; 2006 May; 34(5 Suppl):S160-9. PubMed ID: 16617261
[TBL] [Abstract][Full Text] [Related]
38. Alfa-epoietin and anaemia in gynaecological cancer.
Di Cocco B; Salesi N; Fabi A; Nardoni C; Ferretti G; Bossone G; Ciccarese M; Savarese A; Vecchione A; Cognetti F
Anticancer Res; 2004; 24(2C):1287-92. PubMed ID: 15154662
[TBL] [Abstract][Full Text] [Related]
39. Developments in the therapeutic use of erythropoiesis stimulating agents.
Jelkmann W
Br J Haematol; 2008 May; 141(3):287-97. PubMed ID: 18410567
[TBL] [Abstract][Full Text] [Related]
40. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P
Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
